Healthy Aging Resources to Thrive (HART)
| Status: | Recruiting |
|---|---|
| Healthy: | No |
| Age Range: | 60 - 89 |
| Updated: | 2/28/2019 |
| Start Date: | February 5, 2019 |
| End Date: | March 31, 2023 |
| Contact: | Julie B Cooper, MPA |
| Email: | julie.b.cooper@kp.org |
| Phone: | 206-287-2802 |
Randomized Trial to Reduce Sitting Time and Improve Cardiometabolic Health in Obese Older Adults
Healthy Aging Resources to Thrive (HART) uses a rigorous two-stage randomized control design,
adapted and refined based on pilot studies, to test a novel intervention to reduce sitting
time in older adults. Half the participants will be randomized to the intervention aimed at
decreasing sitting time, and the other half will be randomized to a healthy living control
that does not focus on reduced sitting time. After 6 months, the intervention group will be
further randomized so that half continue with the intervention and the other half receive no
further intervention. All participants will be followed for 12 months.
adapted and refined based on pilot studies, to test a novel intervention to reduce sitting
time in older adults. Half the participants will be randomized to the intervention aimed at
decreasing sitting time, and the other half will be randomized to a healthy living control
that does not focus on reduced sitting time. After 6 months, the intervention group will be
further randomized so that half continue with the intervention and the other half receive no
further intervention. All participants will be followed for 12 months.
Healthy Aging Resources to Thrive (HART) is a two-stage randomized controlled trial (RCT) of
adults over age 60 with obesity to determine the efficacy of a novel sitting-reduction
intervention and its impact on cardiometabolic risk markers. Participants will be randomized
to a 6-month sitting reduction intervention (termed I-STAND) or healthy-living attention
control (Stage 1).
After 6 months, I-STAND participants will be re-randomized to receive either booster sessions
or no further intervention (Stage 2). Attention control participants will receive no further
intervention. All participants will be followed for 12 months total with in person
assessments at baseline 6, and 12 months. Primary outcomes are reduction in sitting time at 6
months, objectively measured using the activPAL device, and blood pressure. The design will
answer novel questions about the impact of sitting reduction on cardiometabolic risk markers
as well as maintenance of sitting reduction.
adults over age 60 with obesity to determine the efficacy of a novel sitting-reduction
intervention and its impact on cardiometabolic risk markers. Participants will be randomized
to a 6-month sitting reduction intervention (termed I-STAND) or healthy-living attention
control (Stage 1).
After 6 months, I-STAND participants will be re-randomized to receive either booster sessions
or no further intervention (Stage 2). Attention control participants will receive no further
intervention. All participants will be followed for 12 months total with in person
assessments at baseline 6, and 12 months. Primary outcomes are reduction in sitting time at 6
months, objectively measured using the activPAL device, and blood pressure. The design will
answer novel questions about the impact of sitting reduction on cardiometabolic risk markers
as well as maintenance of sitting reduction.
Inclusion Criteria: • Self-reported sitting time of 7+ hours per day
- BMI ≥30 and <50 kg/m2
- Able to walk one block
- Able to speak and read English,
- no self-reported vision limitations, sedentary time, use of an assistive device, able
to stand.
- no cognitive impairment that is perceived by the study staff during phone screening
- Willingness to wear device (activPAL)
- Willingness to participate in in-person visits in Seattle
- Willingness to participate in study for a full year
- Continuously enrolled at KP for previous 12 months
- Not on the No Contact list
- Primary care at Group Health Central, Downtown, Northgate, Rainier, Burien, Renton,
Federal Way, Factoria or Bellevue
Exclusion Criteria:
- unable to speak and read English (phone screen)
- unable to walk 1 block (with or without assistive devices) (phone screen)
- self-reported sitting time less than 6 hours per day (phone screen)
- diagnosis codes indicating hearing loss, dementia or serious mental illness (e.g.,
schizophrenia, bipolar disorder), or a terminal or serious illness (e.g., cancer) in
the past 2 years (from the EMR)
We found this trial at
1
site
301 South 320th Street
Seattle, Washington 98023
Seattle, Washington 98023
Principal Investigator: Dori E Rosenberg, PhD, MPH
Phone: 206-287-2802
Click here to add this to my saved trials
